• Datenschutz
  • Impressum
Mittwoch, Juli 9, 2025
Gartenfreunde
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
No Result
View All Result
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
No Result
View All Result
Diabetes was nun?
No Result
View All Result

Startseite » Allgemein » CANKADO contributes to ‚Colloquium Senology 2021/2022‘

CANKADO contributes to ‚Colloquium Senology 2021/2022‘

1. Juli 2021
in Allgemein
Reading Time: 2 min
CANKADO contributes to

A book series on practice-changing developments in breast cancer therapy

Cologne, Germany, 01.07.2021 – The book series, ‘Colloquium Senologie’ targets all doctors that devote themselves to the care of breast cancer patients. Together with their team of authors, the editors describe the practice-relevant developments in breast cancer treatment of the previous twelve months. In addition to the state of the art and important findings from international literature, the work also contains reports from important congresses, such as the annual meeting of the American Society for Clinical Oncology (ASCO).

Prof. Dr. Timo Schinköthe, Founder and CEO of CANKADO GmbH, co-authors for the chapter, ‘Digital Health Applications’ in ‘Colloquium Senologie 2021/2022’. The chapter elaborates on the impact of digital health applications on cancer care and how such digital applications can support patients to actively participate in their respective therapies. The upcoming edition is the tenth release of the book series. This year, the book is launched just four weeks after the ASCO annual conference in 2021 – and it will contain all the practical news from the world’s most important cancer congress.

The launch of the book takes place in an online event programme, ‘ Colloquium Senologie 2021/2022‘, scheduled for July 1st, 2021. As part of the event, participants will have a chance to win the new manual as an e-book or as a printed edition.

CANKADO is a digital health platform with multilingual digital health applications backed by AI (Artificial Intelligence). It is registered as a medical device in the European Union and compliant with the FDA classification for Mobile Medical Devices. The philosophy of Cankado is to improve cancer therapies by predicting adverse events during the treatment of patients in a timely manner, thus improving quality of life and the interaction between health care providers and patients. Cankado also supports pharmaceutical companies as well as Clinical Research Organisations (CROs) in clinical studies. Click here to enquire further information regarding CANKADO’s digital health services.

CANKADO PRO-React Onco is now officially a DiGA (Digitale Gesundheits Anwendung) approved by the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). PRO-React Onco is available for breast cancer patients upon prescription within Germany.

CANKADO Service GmbH is headquartered in Germany and has its own presence in India. Today, CANKADO is the leading system for multi-lingual support of patients with chronic diseases in routine care and in clinical trials, also offering various digital health solutions in the areas of cancer, diabetes, cardiology, surgery, cell therapy, psychology, and nutrition.

  • 0933 Cologne

    https://partners.cankado.com/

  • 0933 Cologne

    https://www.linkedin.com/company/cankado/

Previous Post

CANKADOs Beitrag zum „Colloquium Senologie 2021/2022“

Next Post

Warum Diabetes mellitus nicht nur ein Problem der Bauchspeicheldrüse ist

Related Posts

Maike Sander wird Mitglied der EMBO
Allgemein

Maike Sander wird Mitglied der EMBO

1. Juli 2025
Zuckerfrei naschen liegt im Trend!
Allgemein

Zuckerfrei naschen liegt im Trend!

26. Juni 2025
Zwischen OP-Saal und Erschöpfung
Allgemein

Zwischen OP-Saal und Erschöpfung – Medizin und Gesundheit, Fachmediziner und Wellness

26. Juni 2025
Innovative Therapieansätze für eine bessere Physiotherapie: Wie Melias neue Maßstäbe setzt
Allgemein

Innovative Therapieansätze für eine bessere Physiotherapie: Wie Melias neue Maßstäbe setzt

23. Mai 2025

Beliebte News

  • BEMER Group: Mit der BEMER Matte körperliche Beschwerden lindern

    BEMER Group: Mit der BEMER Matte körperliche Beschwerden lindern

    0 shares
    Share 0 Tweet 0
  • DBLG1-Nutzer Martin über seinen Alltag mit dem Hybrid-Closed-Loop-System

    0 shares
    Share 0 Tweet 0
  • Forschung eröffnet neuen Ansatz für Behandlung von erektiler Dysfunktion

    0 shares
    Share 0 Tweet 0
  • Schmerz lindern mit dem Bemer Pro Set & Bemer Classic Set

    0 shares
    Share 0 Tweet 0
  • Der selbstlernende Algorithmus DBLG1 :

    0 shares
    Share 0 Tweet 0
  • Impressum
  • Datenschutz
© 2020 Diabetes-Wasnun.de
No Result
View All Result
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes